Amplia Therapeutics (ASX:ATX) announced financial results for the quarter ended 30 September 2022.

Recruitment of first patient into ACCENT Phase 2 clinical trial of AMP945 in pancreatic cancer.

Completion of 3-month toxicology studies of AMP945 with no new toxicities noted.

New data for AMP886 showing efficacy in acute myeloid leukemia.

Manufacturing improvements for AMP945 and additional clinical trial supply batches completed.

$1.8m R&D Tax refund received.

Following the announcement the company?s share price unchanged.